Melatonin for Improved Sleep Quality

Melatonin reliably does something for sleep, but the size of that something is smaller than its reputation. Pooled trial data puts the reduction in time to fall asleep at roughly seven minutes, with total sleep time up by about eight minutes and subjective sleep quality modestly better. Those are real, replicated effects — and they are not what most people expect from a product marketed as a sleep aid. Where melatonin genuinely shines is timing rather than sedation. For delayed sleep phase, jet lag, shift work, and circadian disruption in blind adults, it is the best tool available, because it shifts the clock rather than suppressing wakefulness. Used in that role, at the right time of day, results are substantially better than the generic insomnia numbers suggest. The most common mistake is treating it like a sleeping tablet: a large dose taken at bedtime. Smaller doses taken earlier tend to work better.

The pineal gland releases melatonin once light stops reaching the retina, and it acts on MT1 and MT2 receptors in the suprachiasmatic nucleus — the master clock. MT1 activation dampens the clock's wake-promoting drive; MT2 activation shifts the phase of the clock itself. That dual action explains both the mild sleepiness and the larger timing effect. Because phase shifting is directional, timing determines outcome. Taken in the evening, several hours before your own melatonin rise, it advances the clock and makes earlier sleep possible. Taken in the early hours it delays the clock, which is how people accidentally entrench the problem they were trying to fix. Supplemental doses of 3-10 mg produce blood levels many times higher than physiological night-time concentrations. Receptor signalling saturates well below that, which is why larger doses mostly add next-day grogginess rather than more effect.

The 2013 PLoS One meta-analysis of 19 trials in 1,683 participants is the most-cited quantitative summary: sleep onset latency fell by an average of 7.2 minutes, total sleep time rose by 8.2 minutes, and sleep quality scores improved significantly, while sleep efficiency did not. Notably, lower doses performed as well as higher ones. A 2017 systematic review in Sleep Medicine Reviews reached a more nuanced conclusion: the strongest evidence is for reducing sleep onset latency in primary insomnia and for circadian disorders including delayed sleep phase and non-24-hour rhythm in blind adults, with weaker support for increasing total sleep time. A 2007 randomised trial of prolonged-release melatonin in adults aged 55-80 found improved sleep quality and morning alertness, shorter latency, and — importantly — no rebound insomnia or withdrawal on stopping. That last point deserves emphasis. Few sleep interventions can claim clean discontinuation.

Short-term safety is well established. Trials up to six months report side effect rates close to placebo, with headache, daytime sleepiness, dizziness and vivid dreams the most common complaints — most of which respond to lowering the dose. There is no evidence of dependence or of rebound insomnia on stopping, which distinguishes it from sedative hypnotics. Long-term data beyond a year is thinner, particularly in children and adolescents, where questions about effects on pubertal timing have been raised but not demonstrated. Product quality is a genuine issue: analyses of retail melatonin have found actual content ranging from a fraction of the label claim to several times it, and some products contained serotonin. Choose brands with third-party verification. Do not drive or operate machinery for several hours after taking it, and be cautious if you already feel drowsy in the morning on your current dose.